Subsequently, Shen and colleagues also saw no significant difference in percentage of TIM-3 positivity on peripheral CD4+ and CD8+ T cells from glioma patients (13 out of 20 were glioblastoma) versus peripheral CD4+ and CD8+ T cells from healthy controls [102]. This evidence concerns the gene HAVCR2 and glioblastoma.